BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1259 related articles for article (PubMed ID: 26794270)

  • 1. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
    Banks WA
    Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
    Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
    CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
    Al-Ahmady ZS
    Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis.
    Zheng Q; Chen ZX; Xu MB; Zhou XL; Huang YY; Zheng GQ; Wang Y
    Drug Deliv; 2018 Nov; 25(1):1617-1633. PubMed ID: 30334462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnologies: a strategy to overcome blood-brain barrier.
    De Rosa G; Salzano G; Caraglia M; Abbruzzese A
    Curr Drug Metab; 2012 Jan; 13(1):61-9. PubMed ID: 22292810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.
    Morales JF; Montoto SS; Fagiolino P; Ruiz ME
    Mini Rev Med Chem; 2017; 17(3):247-257. PubMed ID: 27739359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New experimental models of the blood-brain barrier for CNS drug discovery.
    Kaisar MA; Sajja RK; Prasad S; Abhyankar VV; Liles T; Cucullo L
    Expert Opin Drug Discov; 2017 Jan; 12(1):89-103. PubMed ID: 27782770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of nano-therapeutics for major disorders of the central nervous system.
    Gao H; Pang Z; Jiang X
    Pharm Res; 2013 Oct; 30(10):2485-98. PubMed ID: 23797465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system.
    Crawford L; Rosch J; Putnam D
    J Control Release; 2016 Oct; 240():251-266. PubMed ID: 26724368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
    Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
    Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential receptor-mediated drug targeting to the diseased brain.
    Rip J; Schenk GJ; de Boer AG
    Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crossing the Blood-Brain Barrier: A Review on Drug Delivery Strategies for Treatment of the Central Nervous System Diseases.
    Mansor NI; Nordin N; Mohamed F; Ling KH; Rosli R; Hassan Z
    Curr Drug Deliv; 2019; 16(8):698-711. PubMed ID: 31456519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.